Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 8;4(6):635-645.
doi: 10.1002/ags3.12397. eCollection 2020 Nov.

Precision medicine for adjuvant chemotherapy of resected colorectal cancer

Yuji Miyamoto  1 , Yukiharu Hiyoshi  1 , Hiroshi Sawayama  1 , Ryuma Tokunaga  1 , Hideo Baba  1
Affiliations
Review

Precision medicine for adjuvant chemotherapy of resected colorectal cancer

Yuji Miyamoto et al. Ann Gastroenterol Surg. .

Abstract

Colorectal cancer (CRC) is the most common cancer and the second leading cause of cancer death in Japan. Surgical resection is the only curative option for localized disease. However, undetectable micrometastases remaining after curative surgery may cause disease recurrence. Adjuvant chemotherapy aims to eradicate these micrometastases to improve the cure rate. Unfortunately, few reliable prognostic and predictive markers are available that identify patients at high risk for CRC during early-stage disease. However, promising biomarkers may become available in the near future. Such biomarkers provide information for stratifying a patient's risk and for selecting the optimal treatment. Here, we provide an overview of current relevant prognostic and predictive biomarkers applicable to adjuvant treatment of early-stage CRC and focus on the future of this field.

Keywords: adjuvant chemotherapy; colorectal cancer; precision medicine; predictive marker; prognostic marker.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Cancer Registry and Statistics . Cancer Information Service, National Cancer Center, Japan.
    1. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2019;25(1):1–42. - PMC - PubMed
    1. Matsuda C, Ishiguro M, Teramukai S, Kajiwara Y, Fujii S, Kinugasa Y, et al. A randomised‐controlled trial of 1‐year adjuvant chemotherapy with oral tegafur–uracil versus surgery alone in stage II colon cancer: SACURA trial. Eur J Cancer. 2018;96:54–63. - PubMed
    1. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, et al. The benefit of leucovorin‐modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C‐03. J Clin Oncol. 1993;11(10):1879–87. - PubMed
    1. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International multicentre pooled analysis of colon cancer trials (IMPACT) investigators. Lancet (London, England). 1995;345(8955):939–44. - PubMed